Combination of Antihypertensive therapy in the elderly, Multicenter Investigation <CAMUI> Multi-center randomized controlled study on efficacy of ARB/Diuretic mixture versus ARB/Ca channel blocker combination therapy to blood pressure or cognitive function in the elderly patients who have insufficient controlled hypertension in ARB monotherapy

Combination of Antihypertensive therapy in the elderly, Multicenter Investigation <CAMUI> Multi-center randomized controlled study on efficacy of ARB/Diuretic mixture versus ARB/Ca channel blocker combination therapy to blood pressure or cognitive function in the elderly patients who have insufficient controlled hypertension in ARB monotherapy - Combination of Antihypertensive therapy in the elderly, Multicenter Investigation <CAMUI>

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001688

Enrollment

200

Registered

2009-02-05

Start date

2008-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

PREMINENT group To 3 month: PREMINENT (combination drug: Losartan 50 mg/HCTZ 12.5 mg) From 4 to 6 month: ARB addded if needed. From 7 to 12 month: alpha blocker, beta blocker, and/or centrally act

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with essential hypertension, who have been previously treated with ARB monotherapy (Losartan 50 mg, candesartan 8 mg, valsartan 80 mg, telmisartan 40 mg, or olmesartan 20 mg) for more than a month and whose blood pressure has not been adequately controlled with the treatment (SBP >=140 mmHg and/or DBP >=90mmHg:In the case of diabetes or renal disease, SBP >=130 mmHg and/or DBP >=80mmHg). 2) 65 years age or more 3) Both gender is included 4) Outpatients 5) Patient understands study procedures and agrees to participate in the study by giving written informed consent prior to the study start.

Exclusion criteria

Exclusion criteria: 1) Patients with the secondary hypertension 2) Patients with heart failure: >= NYHA grade III 3) Patient with a history of severe renal disease: serum creatinine>= 2.0 mg/dl 4) Patients with critical liver damage: ALT or ASTis 3 times of normal upper level or more 5) Patients with a history of hypersensitivity to PREMINENT 6) Patients with a history of hypersensitivity to components of thiazide or similar compounds 7) Patients who are considered to be not eligible to the study by the investigator due to medical reasons

Design outcomes

Primary

Measure	Time frame
Systolic/Diastolic blood pressure change during three month treatment.	—

Secondary

Measure	Time frame
MMSE score change. The rate of achieving the target blood pressure. The change of laboratory test results, including as HbA1c, HOMA-R, FBS, UP, microalbuminuria, K, and uric acid. The rate of continued treatment and the compliance of the treatment. Rates of adverse experiences	—

Countries

Japan

Contacts

Public ContactNobuyuki Sato

Asahikawa Medical College Cardiovascular Division, Department of Internal Medicine

0166-68-2442

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026